Citations

Clear

29 citation(s) found for "May, Heather".

1086: IMPACT OF THE AKI IN CARE TRANSITIONS (ACT) PROGRAM ON KIDNEY HEALTH KNOWLEDGE AND QUALITY OF LIFE
Schreier, Diana J., Anderson, Brenda J., Meade, Laurie, Tinaglia, Angeliki G. , Andrea, Kattah, Frazee, Erin N. , May, Heather P. , Anderson, Brenda, Rule, Andrew D. , Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 538-538

10.1097/01.ccm.0000910072.40722.59 Get It

High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
O'Donoghue, Darragh, Truong, Huong L. , Finnes, Heidi D. , May, Heather P. , Ansell, Stephen M. , Bennani, N. Nora , Habermann, Thomas M. , Inwards, David J. , Johnston, Patrick B. , Khurana, Arushi , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Porrata, Luis F. , Thanarajasingam, Gita , Thompson, Carrie A. , O'Donoghue, Darragh F, Personett, Heather A. , Ansell, Stephen M , Bennani, N Nora , Habermann, Thomas , Micallef, Ivana N , Nowakowski, Grzegorz S , Paludo, Jonas , Thanarajasingam, Gita , Thompson, Carrie A , Villasboas, Jose Caetano , Wang, Yucai , Witzig, T.E. , Leung, Nelson , McDonald, Jennifer S. , Lin, Yi , Paludo, Jonas , Villasboas, José C. , Wang, Yucai , Witzig, Thomas E. , Leung, Nelson

Mayo Clinic

JCO Oncology Practice | October 14, 2022 | Volume: 18 | Issue: 12 | Pages: e1908-e1917

10.1200/op.22.00182 | PMID 36240468 Get It

PURPOSE:High-dose methotrexate (HDMTX; > 500 mg/m2) is an important component of lymphoma therapy. Serum MTX monitoring at 48 hours is the standard approach to identify those at increased risk of developing MTX toxicity. Our aim was to characterize the incidence of complications and their association with MTX levels.METHODS:A retrospective review of our institutional electronic medical record was conducted to identify patients with lymphoma who received HDMTX between January 1, 2002, and December 31, 2018. We characterized the incidence of acute kidney injury (AKI), intensive care unit (ICU) admission, length of hospital stay (LOS), and 30-day mortality across 48-hour MTX levels. To establish an association between 48-hour MTX levels and the complications listed, we performed chi-square analysis for dichotomous variables and Kruskal-Wallis for nonparametric data. Receiver operator characteristic curve analysis was performed to identify the MTX level where AKI grade ≥ 2 was more likely. Multivariate logistic regression analysis was performed to identify risk factors for this MTX level.RESULTS:We identified 642 patients with 2,804 cycles of HDMTX. The incidence of AKI was 19.1% with AKI grade ≥ 2 making up 21% of cases. Rates of AKI, ICU admission, and 30-day mortality are associated with elevated 48-hour MTX levels. There was a significant increase in median LOS with elevated MTX levels ( P < .001). Receiver operator characteristic curve analysis for AKI grade ≥ 2 demonstrated a 48-hour MTX level threshold of 1.28 μmol/L. Multivariate logistic regression analysis revealed age, male sex, elevated body surface area, higher MTX dose, monotherapy, and first cycle as independent factors.CONCLUSION:Elevated MTX levels are associated with a significant increased rate of AKI, ICU admission, prolonged LOS, and 30-day mortality. Elevated 48-hour MTX levels, particularly > 1.28 μmol/L, should alert clinicians for complications and to initiate measures to reduce MTX levels.
A Systematic Review and Meta-Analysis Evaluating Geographical Variation in Outcomes of Cancer Patients Treated in ICUs
Nazer, Lama , López-Olivo, María A. , Brown, Anne Rain , Sirimaturos, Michael , Habash, Khader , Al‐Qadheeb, Nada S. , Milano, Victoria, Taylor, Amy , Nates, Joseph L. , May, Heather, Cuenca, John A. , May, Heather P.

Mayo Clinic

Critical Care Explorations | September 13, 2022 | Volume: 4 | Issue: 9 | Pages: e0757

10.1097/cce.0000000000000757 | PMID 36119395 Get It

OBJECTIVES: The reported mortality rates of cancer patients admitted to ICUs vary widely. In addition, there are no studies that examined the outcomes of critically ill cancer patients based on the geographical regions. Therefore, we aimed to evaluate the mortality rates among critically ill cancer patients and provide a comparison based on geography. DATA SOURCES: PubMed, EMBASE, and Web of Science. STUDY SELECTION: We included observational studies evaluating adult patients with cancer treated in ICUs. We excluded non-English studies, those with greater than 30% hematopoietic stem cell transplant or postsurgical patients, and those that evaluated a specific type of critical illness, stage of malignancy, or age group. DATA EXTRACTION: Two reviewers independently applied eligibility criteria, assessed quality, and extracted data. Studies were classified based on the continent in which they were conducted. Primary outcomes were ICU and hospital mortality. We pooled effect sizes by geographical region. DATA SYNTHESIS: Forty-six studies were included (n = 110,366). The overall quality of studies was moderate. Most of the published literature was from Europe (n = 22), followed by North America (n = 9), Asia (n = 8), South America (n = 5), and Oceania (n = 2). Pooled ICU mortality rate was 38% (95% CI, 33–43%); the lowest mortality rate was in Oceania (26%; 95% CI, 22–30%) and highest in Asia (51%; 95% CI, 44–57%). Pooled hospital mortality rate was 45% (95% CI, 41–49%), with the lowest in North America (37%; 95% CI, 31–43%) and highest in Asia (54%; 95% CI, 37–71%). CONCLUSIONS: More than half of cancer patients admitted to ICUs survived hospitalization. However, there was wide variability in the mortality rates, as well as the number of available studies among geographical regions. This variability suggests an opportunity to improve outcomes worldwide, through optimizing practice and research.
Optimising transitions of care for acute kidney injury survivors: protocol for a mixed-methods study of nephrologist and primary care provider recommendations
May, Heather P. , Krauter, Abby K, Finnie, Dawn M., McCoy, Rozalina G. , Frazee, Erin N. , Personett, Heather A. , McCoy, Rozalina Grubina , Kashani, Kianoush , Griffin, Joan M.

Mayo Clinic

BMJ Open | June 22, 2022 | Volume: 12 | Issue: 6 | Pages: e058613

10.1136/bmjopen-2021-058613 | PMID 35732395 Get It

Introduction Acute kidney injury (AKI) affects nearly 20% of all hospitalised patients and is associated with poor outcomes. Long-term complications can be partially attributed to gaps in kidney-focused care and education during transitions. Building capacity across the healthcare spectrum by engaging a broad network of multidisciplinary providers to facilitate optimal follow-up care represents an important mechanism to address this existing care gap. Key participants include nephrologists and primary care providers and in-depth study of each specialty’s approach to post-AKI care is essential to optimise care processes and healthcare delivery for AKI survivors. Methods and analysis This explanatory sequential mixed-methods study uses survey and interview methodology to assess nephrologist and primary care provider recommendations for post-AKI care, including KAMPS (kidney function assessment, awareness and education, medication review, blood pressure monitoring and sick day education) elements of follow-up, the role of multispecialty collaboration, and views on care process-specific and patient-specific factors influencing healthcare delivery. Nephrologists and primary care providers will be surveyed to assess recommendations and clinical decision-making in the context of post-AKI care. Descriptive statistics and the Pearson’s χ 2 or Fisher’s exact test will be used to compare results between groups. This will be followed by semistructured interviews to gather rich, qualitative data that explains and/or connects results from the quantitative survey. Both deductive analysis and inductive analysis will occur to identify and compare themes. Ethics and dissemination This study has been reviewed and deemed exempt by the Institutional Review Board at Mayo Clinic (IRB 20–0 08 793). The study was deemed exempt due to the sole use of survey and interview methodology. Results will be disseminated in presentations and manuscript form through peer-reviewed publication.
Development and Feasibility of a Multidisciplinary Approach to AKI Survivorship in Care Transitions: Research Letter
Frazee, Erin N. , Schreier, Diana J., Meade, Laurie A., Anderson, Brenda, Rensing, Megan E., Ruud, Kari L., Kattah, Andrea G. , Finnie, Dawn M., Herges, Joseph R. , Group, For the ACT Study, Frazee, Erin N , Anderson, Brenda K, Kattah, Andrea G , May, Heather P. , Rule, Andrew D. , McCoy, Rozalina G. , Kashani, Kianoush , Group, For the ACT Study

Mayo Clinic

Canadian Journal of Kidney Health and Disease | March 7, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/20543581221081258 | PMID 35284082 Get It

Background: Acute kidney injury (AKI) survivors are at heightened risk for poor short- and long-term health outcomes. Even among those who recover after an AKI episode, the risk for chronic kidney disease is 4- to 6-fold higher than in patients without AKI, underscoring the importance of identifying methods to improve AKI survivorship. Objective: The purpose of this report was to describe the development and feasibility of a novel multidisciplinary approach to caring for AKI survivors at care transitions (ACT). Design: Observational process improvement initiative. Setting: Single academic medical center in the United States. Patients: The studied population was adults with stage 3 AKI not discharging on dialysis who were established with a primary care provider (PCP) at our institution. Methods: An electronic health record tool was developed prior to implementation to identify AKI survivors. The ACT program encompassed engaging patients in the hospital, delivering education by nephrology-trained nurses before discharge, completing recommended laboratory testing after discharge, and conducting structured kidney-focused follow-up with a pharmacist and a PCP within 7 to 14 days after discharge. Patients could be referred for nephrology evaluation at the discretion of the PCP. Results: Preliminary data demonstrated that most AKI survivors of interest could be identified, educated, and followed up with this model. This strategy appeared feasible, scalable, and maximized the unique expertise of each member of the multidisciplinary team. Limitations: Small sample size, future assessment of process, clinical, and patient-reported outcomes needed. Conclusions: The multidisciplinary ACT workflow supported by clinical decision support was feasible and addressed gaps in existing care transition models. Team-based care delivery in primary care appears to be a mechanism to extend the capacity for kidney health monitoring for AKI survivors.
481: A META-ANALYSIS EVALUATING OUTCOMES OF CRITICALLY ILL CANCER PATIENTS BY GEOGRAPHICAL REGION
Nazer, Lama , Habash, Khader , Sirimaturos, Michael , Al‐Qadheeb, Nada S. , Milano, Victoria, Taylor, A., Nates, Joseph, López-Olivo, María A. , Cuenca, John A. , Brown, Anne Rain , May, Heather P. , Taylor, Amy, Nates, Joseph L.

Mayo Clinic

Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 231-231

10.1097/01.ccm.0000808248.89417.0c Get It

477: SYSTEMATIC REVIEW AND META-ANALYSIS OF MORTALITY IN CANCER PATIENTS TREATED IN INTENSIVE CARE UNITS
Nazer, Lama , Sirimaturos, Michael , Habash, Khader , Al‐Qadheeb, Nada S. , Milano, Victoria, Nates, Joseph, Brown, Anne Rain , Cuenca, John A. , López-Olivo, María A. , May, Heather P. , Taylor, Amy Grace Stephanie , Nates, Joseph L.

Mayo Clinic

Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 229-229

10.1097/01.ccm.0000808232.23200.d0 Get It

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*
Gutierrez, Cristina, Brown, Anne Rain T., May, Heather P., Beitinjaneh, Amer, Stephens, R. Scott, Rajendram, Prabalini, Nates, Joseph L., Pastores, Stephen M., Dharshan, Ananda, Moraes, Alice Gallo de, Hensley, Matthew K., Feng, Lei, Brudno, Jennifer N., Athale, Janhavi, Ghosh, Monalisa, Kochenderfer, James N., Arias, Alejandro S., Lin, Yi, McEvoy, Colleen, Mead, Elena, Westin, Jason, Kostelecky, Natalie, Mian, Agrima, Herr, Megan M., Lin, Yi , Beitinjaneh, Amer , Kochenderfer, James N. , Brown, Anne Rain , De Moraes, Alice Gallo, Lin, Yi , Gutierrez, Cristina, Brown, Anne Rain T., May, Heather P., Stephens, R. Scott, Rajendram, Prabalini, Nates, Joseph L., Pastores, Stephen M., Dharshan, Ananda, Moraes, Alice Gallo de, Hensley, Matthew K., Feng, Lei, Brudno, Jennifer N., Athale, Janhavi, Ghosh, Monalisa, Arias, Alejandro S., Lin, Yi, McEvoy, Colleen, Mead, Elena, Westin, Jason, Kostelecky, Natalie, Mian, Agrima, Herr, Megan M.

Mayo Clinic

Critical Care Medicine | July 5, 2021 | Volume: 50 | Issue: 1 | Pages: 81-92

10.1097/ccm.0000000000005149 | PMID 34259446 Get It

OBJECTIVES: To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. DESIGN: Retrospective cohort study SETTING: Nine centers across the U.S. part of the chimeric antigen receptor-ICU initiative. PATIENTS: Adult patients treated with chimeric antigen receptor T-cell therapy who required ICU admission between November 2017 and May 2019. INTERVENTIONS: Demographics, toxicities, specific interventions, and outcomes were collected. RESULTS: One-hundred five patients treated with axicabtagene ciloleucel required ICU admission for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome during the study period. At the time of ICU admission, the majority of patients had grade 3–4 toxicities (66.7%); 15.2% had grade 3–4 cytokine release syndrome and 64% grade 3–4 immune effector cell-associated neurotoxicity syndrome. During ICU stay, cytokine release syndrome was observed in 77.1% patients and immune effector cell-associated neurotoxicity syndrome in 84.8% of patients; 61.9% patients experienced both toxicities. Seventy-nine percent of patients developed greater than or equal to grade 3 toxicities during ICU stay, however, need for vasopressors (18.1%), mechanical ventilation (10.5%), and dialysis (2.9%) was uncommon. Immune Effector Cell-Associated Encephalopathy score less than 3 (69.7%), seizures (20.2%), status epilepticus (5.7%), motor deficits (12.4%), and cerebral edema (7.9%) were more prevalent. ICU mortality was 8.6%, with only three deaths related to cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Median overall survival time was 10.4 months (95% CI, 6.64–not available mo). Toxicity grade or organ support had no impact on overall survival; higher cumulative corticosteroid doses were associated to decreased overall and progression-free survival. CONCLUSIONS: This is the first study to describe a multicenter cohort of patients requiring ICU admission with cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Despite severe toxicities, organ support and in-hospital mortality were low in this patient population.
Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome
May, Heather P. , Mara, Kristin C. , Frazee, Erin N. , Leung, Nelson , Frazee, Erin N , Personett, Heather A. , Leung, Nelson , Mara, Kristin C , Habermann, Thomas M.

Mayo Clinic

Leukemia & Lymphoma | June 25, 2021 | Volume: 62 | Issue: 13 | Pages: 3152-3159

10.1080/10428194.2021.1941931 | PMID 34169786 Get It

Ideal Body Weight-Based Dosing of Rabbit Antithymocyte Globulin for Cost Minimization in Kidney Transplantation
Bubik, Rachel J. , Peterson, Kristen , Myhre, Laura J., Bernard, Stacy A. , Dean, Patrick G. , May, Heather P. , Peterson, Kristen T, Dean, Patrick, Personett, Heather A. , Bailen, Rachel J

Mayo Clinic

Progress in Transplantation | March 18, 2021 | Volume: 31 | Issue: 2 | Pages: 184-189

10.1177/15269248211003257 | PMID 33733917 Get It

Introduction: Contemporary dosing strategies for rabbit anti-thymocyte globulin (rATG) in kidney transplantation aim to reduce cumulative exposure, minimizing long-term adverse events. The use of ideal body weight-based dosing has been trialed, however concern for increased rejection post-transplant exists due to lower doses of rATG. Research Questions: The primary aim of this study was to compare rejection rates between rATG dosing protocols using actual body weight and ideal body weight and secondarily to evaluate cost savings following protocol implementation. Design: This was a retrospective study surrounding implementation of an ideal body weight-based dosing protocol for rATG. We compared 75 kidney transplant recipients in whom rATG was dosed based on actual body weight (pre-protocol group) to 64 in whom dosing was based on ideal body weight (post-protocol group), following a nine-month washout. Results: The mean cumulative rATG dose in the pre-protocol group was 6.3 mg/kg of actual body weight. When ideal body weight was used in the post-protocol group, the mean dose was 4.5 mg/kg of actual body weight. The rejection rate was 18.7% pre-protocol and 23.4% postprotocol, which did not represent a statistically significant difference (p = 0.491). The actual annual cost savings after protocol implementation exceeded $162,000, approximately $2,500 per patient. Conclusion: Results suggest ideal body weight-based dosing of rATG may reduce exposure and cost, without significantly impacting the risk of rejection in kidney transplant recipients. More studies are needed to confirm these findings.